Skip to main content

Table 6 Current and recent perioperative gene and vaccine therapy trials for MIBC*

From: Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review

Institution Therapy Trial description Status/Outcomes Trial ID
Uppsala University Gene Phase 1/IIa Intravesical instillation of AdCD40L that may improve anti-tumor immune response. Cystectomy followed phase 1 trial. Completed. 8 patients with limited complications. Successful gene transfer detected in biopsies [33]. NCT00891748
Celldex Therapeutics Vaccine Phase II neoadjuvant and adjuvant administration of CDX-1307 vaccine with chemotherapy for bladder tumors expressing B-HCG protein for patients undergoing radical cystectomy. Terminated due to lack of enrollment. NCT01094496
MSKCC and NCI Vaccine Phase 1 adjuvant administration of NY-ESO-1 peptide vaccine with BCG + sargramostim for tumors expressing NY-ESO-1 or LAGE-1 antigens. Patients previously underwent radical cystectomy. Competed. Results unreported. NCT00070070
  1. *Table does not include trials for multiple solid tumors that may include bladder cancer as a subset.
  2. MSKCC = Memorial Sloan-Kettering Cancer Center.
  3. NCI = National Cancer Institute.